ArticleESMO gastrointestinal oncology2026
Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in patients with microsatellite-stable/DNA mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer (CRC). Based on data suggesting antitumor synergy between ICIs and MEK inhibitors, the phase II CheckMate 142 trial evaluated the combination of nivolumab, ipilimumab, and cobimetinib in a cohort of patients with previously treated MSS/pMMR metastatic CRC. Patients and methods: Patients received nivolumab (3 mg/kg every 2 weeks), ipilimumab (1 mg/kg every 6 weeks), and cobimetinib [60 mg daily in 28-day cycles (21 days on/7 days off)]. The primary endpoint was investigator-assessed objective response rate (ORR) using RECIST v1.1. Results: After a median (range) follow-up of 59.5 (53.9-67.5) months, investigator-assessed ORR in 30 treated patients was 3% ( Conclusions: The combination of nivolumab, ipilimumab, and cobimetinib had limited clinical activity in patients with previously treated MSS/pMMR mCRC. Further investigation of this regimen is not warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.